



# The genomics of schizophrenia: update and implications

Paola Giusti-Rodríguez<sup>1</sup> and Patrick F. Sullivan<sup>1,2,3</sup>

<sup>1</sup>Department of Genetics, Center for Psychiatric Genomics, and <sup>2</sup>Department of Psychiatry, University of North Carolina, Chapel Hill, North Carolina, USA.

<sup>3</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

**Schizophrenia is strongly familial yet rarely (if ever) exhibits classical Mendelian inheritance patterns. The advent of large-scale genotyping and sequencing projects has yielded large data sets with higher statistical power in an effort to uncover new associations with schizophrenia. Here, we review the challenges in dissecting the genetics of schizophrenia and provide an update of the current understanding of the underlying genomics. We discuss the breadth of susceptibility alleles, including those that may occur with low frequency and high disease risk, such as the 22q11.2 hemideletion, as well as alleles that may occur with greater frequency but convey a lower risk of schizophrenia, such as variants in genes encoding subunits of the voltage-gated L-type calcium channel. Finally, we provide an overview of the clinical implications for the diagnosis and treatment of schizophrenia based on progress in understanding the underlying genetic basis.**

## Introduction

Schizophrenia is a debilitating psychiatric disorder that remains enigmatic long after its first description over 100 years ago. In spite of considerable research efforts, its pathophysiology remains poorly understood. As with most psychiatric conditions, the clinical and research definitions of schizophrenia are based on constellations of signs and symptoms (1) and are thus usually considered “disorders” instead of “diseases.” Unlike many other medical conditions, there are no objective clinical or pathological features of high sensitivity and specificity to enable greater precision in the diagnosis of schizophrenia. The onset of schizophrenia is typically in adolescence or early adulthood, and the course of illness is often lifelong and typified by exacerbations, remissions, substantial residual symptoms, and functional impairment. Schizophrenia thus has an immense impact on public health and is among the five leading causes of disability worldwide (2). Individuals affected by schizophrenia have elevated morbidity and mortality, a lifetime risk of suicide exceeding 10%, and substantial comorbidity with other psychiatric disorders, including major depressive disorder and substance abuse (refs. 3–5 and Table 1). The significant societal, familial, and personal impacts of schizophrenia underscore the pressing need for more effective preventive, diagnostic, and treatment strategies.

Major efforts by the psychiatric genetics community — aided by exceptional advances in technology and knowledge of the genome — have transformed this field and have identified multiple robust and replicable findings. We believe it timely to provide an update on the genomics of schizophrenia, along with consideration of its implications.

## Risk factors for schizophrenia

Results from over 40 years of epidemiological and genetic epidemiological studies have converged on the conclusion that schizophrenia is a complex disorder, with both genetic and environmental determinants. Family history is a strong and widely replicated

risk factor, and the heritability of schizophrenia (the proportion of variance in liability due to additive genetic factors) is relatively high, exceeding 60% in two national family studies and 80% in twin studies (Table 1). Multiple lines of inquiry also show important environmental influences that affect risk for schizophrenia (refs. 6–9 and Table 1). Perinatal and early childhood events, including maternal stress and infection, growing up in urbanized areas, and being part of an immigrant group all increase risk of developing schizophrenia (9). Viral infections of the central nervous system during development may also play an important role (10).

## The logic behind genomic approaches to schizophrenia

Assessment of the genome is increasingly complete, tractable, and cost effective. It is now routine to screen the whole genome for many types of genetic changes in large samples. In contrast, environmental assessment is often considerably more difficult — there is no single comprehensive technology to screen an individual’s “environment,” prospective assessments in large samples can be prohibitively expensive, and retrospective assessments are prone to measurement error. Thus, even as both genes and environment are involved in the etiology of schizophrenia, many researchers have reasoned that capitalizing on the family history risk factor via genomic studies is a logical starting point.

Due to its high heritability and strong familial associations, genetic approaches are critically important for the study of schizophrenia. Yet, until recently, progress had been disappointingly slow. The Human Genome Project, the International HapMap Project, the 1000 Genomes Project, and ENCODE have yielded unprecedented increases in knowledge about the sequence of the human genome, the location and prevalence of genetic variation, and biological regulatory processes (11–14). These advances have provided a fertile ground for research discoveries about the genetic basis of schizophrenia and other complex disorders.

In the last five years, as the psychiatric genetics community has adopted rigorous standards for the analysis of genetic data, replication and confidence in genetic findings has increased (15, 16). These advances have resulted from a convergence of factors. The large-scale genome projects mentioned above (e.g., HapMap) also catalyzed technological advances in genotyping, sequencing, analy-

**Conflict of interest:** Patrick F. Sullivan was on the scientific advisory board of Expression Analysis.

**Citation for this article:** *J Clin Invest.* 2013;123(11):4557–4563. doi:10.1172/JCI66031.

**Table 1**  
Features of schizophrenia

Features	Associated details
Lifetime prevalence	0.4% (98)
Morbidity	Leading worldwide cause of disability (2) Licit and illicit drug and alcohol use disorders (4) Cardiovascular disease (99) Type 2 diabetes mellitus (100)
Mortality	12- to 15-year decrease in life expectancy (99, 101)
Lifetime cost	\$1.4 million per person (102)
Epidemiological risk factors (9)	Family history Season of birth Urban birth Immigration Perinatal infection Famine
Heritability	64% (95% CI, 62%–67%), Swedish national family study (6) 67% (95% CI, 64%–71%), Danish national family study (8) 81% (95% CI, 73%–90%), twin study meta-analysis (7)
Genetic loci (30)	No Mendelian variants CNVs Common SNPs Uncommon/rare exonic variants
Estimated SNPs	6,000–10,000 independent common variants that together account for ~50% of variance in liability (66)

sis, and bioinformatics as well as marked decreases in cost. In addition, accrual of very large sample sizes, which has only been possible through consortia, has been critical for achieving improved statistical power. One of many consortia in psychiatry, the Psychiatric Genomics Consortium (PGC) (17), has orchestrated large-scale mega-analyses for schizophrenia and other major psychiatric disorders (18–20). The PGC has more than 375 investigators from 22 countries and has approximately 125,000 cases and controls with genome-wide association study (GWAS) data under analysis and is the largest consortium in the history of psychiatry.

### Genomic results for schizophrenia

Multiple approaches have been applied to understand the genetic basis of schizophrenia. Accumulating data indicate a role for both rare and common variants in increasing risk for schizophrenia. Current studies suggest multiple robust and replicable genomic findings for schizophrenia (Figure 1). These susceptibility alleles occur with varying degrees of frequency and confer different risks of disease development, as discussed below. Surprisingly, the genetic basis for schizophrenia has multiple points of convergence with other psychiatric disorders that have different clinical features, such as autism and bipolar disorder (20–26). With further work, it is possible, and perhaps likely, that these results will lead to revisions in psychiatric nosology or the fundamental ways in which we classify and approach these disorders.

*Mendelian forms of schizophrenia.* Notably, no Mendelian forms of schizophrenia (i.e., rare mutations with deterministic effects) have been identified via standard medical genetics approaches or genomics studies (Figure 1A, i). Although generations of physicians have evaluated the family histories of probands with

schizophrenia, few (if any) highly compelling instances of pedigrees in which schizophrenia segregates in Mendelian fashion exist. While some consider disrupted in schizophrenia 1 (*DISC1*) as an example of this class of mutation, critical review of the empirical data does not strongly support this conclusion (27). The notion that schizophrenia exhibits non-Mendelian inheritance was bolstered by a sequencing study focusing on individuals with exceptionally early-onset and treatment-resistant schizophrenia, which identified no clear exonic mutations (28). Mendelian subforms have been identified for multiple other psychiatric disorders (e.g., Alzheimer's disease, autism, and mental retardation).


*Copy number variants.* Changes in the number of copies of DNA from the expected values are known as copy number variants (CNVs) and result from the deletion (del) or duplication (dup) of a relatively large genomic region (29). As a consequence, the “dosages” of one or more genes in the region are altered and can exert a profound effect on risk for disease. Multiple rare CNVs are now established risk factors for psychiatric disorders, including schizophrenia, mental retardation, and autism (22, 29–33). This class of variants has a high genotypic relative risk (Figure 1A, ii).

Eight CNVs have a strong effect on disease risk (genotypic relative risks 4–20) and have been consistently associated with psychiatric disorders (29, 30, 34). Two CNVs impact single genes: 2p16.3 del (*neurexin 1* [*NRXN1*]) (35) and 7q36.3 dup (*vasoactive intestinal peptide receptor 2* [*VIPR2*]) (36). Others alter the dosages of many genes: 1q21.1 del/dup (34 genes) (37–41), 3q29 del (19 genes) (34, 37, 42), 7q11.23 dup (25 genes) (37, 43, 44), 15q11.2 dup (70 genes) (39, 45), 15q13.3 del/dup (12 genes) (38, 39, 46), 16p13.11 dup (47, 48) (8 genes), 16p11.2 del/dup (29 genes) (49–53), 17q12 del (18 genes) (54), and 22q11.2 del/dup (53 genes) (45, 55).

The studies that established these associations evaluated cases and controls. Without parental data, these CNVs could have been inherited from a parent or arisen *de novo*. *De novo* CNVs have been widely studied in autism (44). In schizophrenia, there are fewer studies, although increased rates of *de novo* CNVs have been reported in cases with schizophrenia (37).

Although these CNVs are rare and relatively potent risk factors, they often involve many genes and are not specific, as risk is often increased for multiple psychiatric disorders. These complexities limit their utility for understanding the specific genes contributing to schizophrenia. Further work is needed to probe the contribution of the genes within many of these multigenic CNVs in order to understand their contribution to disease. Nonetheless, pathway analysis of genes in these CNVs suggests an overrepresentation of genes associated with neuronal function, providing a context for future research (37, 56).

The 16p11.2 CNV has been associated with both autism and schizophrenia. Deletion and duplication of this CNV are also associated with increased and reduced head and body size, respectively

**Figure 1**

The genetic landscape of schizophrenia. **(A)** The allelic spectrum of schizophrenia. Shown are high-confidence empirical findings of the contribution of rare and common variants to the genotypic relative risk for developing schizophrenia. The x axis depicts the  $\log_{10}$  of allele frequency in controls, and the y axis depicts the point estimate for  $\log_{10}$  of the genotypic relative risk. (i) No Mendelian variants for schizophrenia are known. A Mendelian form of schizophrenia would be expected to be rare with a very high genotypic relative risk ( $>50$ ). (ii) CNVs associated with schizophrenia (represented by diamonds) are uncommon or rare and have an intermediate to high genotypic relative risks. (iii) Whole-exome sequencing studies have yet to identify protein-altering variants in this region, but the extant studies are few and small. (iv) High-confidence exclusion zone defined by risk allele prevalence  $>0.1$  and genotypic relative risk  $>1.16$ , in which no loci have been identified despite statistical power nearing 100%. (v) Approximately 22 common variants have been significantly associated with schizophrenia to date (red circles). Common variants have a low genotypic relative risk individually but together account for more than 50% of the heritability of schizophrenia. **(B)** Expanded view of v, identifying the genomic regions achieving genome-wide significance. Circles denote the 22 common variants that have been significantly associated with schizophrenia; green circles represent long intergenic noncoding RNAs (lincRNAs).

(49, 50, 52). The 16p11.2 CNV encompasses 29 genes; systematic overexpression and inhibition of each gene in zebrafish suggested that the potassium channel tetramerization domain containing 13 gene (*kctd13*) might be the key determinant in the region, as the brain size phenotypes mirrored those in humans (57).

**Uncommon or rare exonic variation.** Recent improvements in technology have enabled the evaluation of most of the protein-coding regions of the genome (the “exome”) via high-throughput sequencing. This is currently an area of intense interest, because the confident identification of rare or uncommon exonic variants of strong effect could be particularly valuable (Figure 1A, iii). Any such variant would pinpoint a single key gene and probably be amenable to current molecular biology and neurobiology methods.

A few small exome sequencing studies of schizophrenia have been published (larger studies have been submitted for publication). Xu et al. carried out exome sequencing of 231 trios with no family history (i.e., “sporadic” cases) and 34 unaffected trios (58, 59). Four genes with modest statistical evidence were highlighted by the authors (dihydropyrimidine dehydrogenase [*DPYD*], laminin,  $\alpha$  2

[*LAMA2*], transformation/transcription domain-associated protein [*TRRAP*], and vacuolar protein sorting 39 [*VPS39*]), and the authors suggested that in aggregate cases with schizophrenia had an increased burden of de novo variation (58). An exome sequencing study of 14 schizophrenia probands and their parents found more de novo mutations (60). Evaluation of 166 schizophrenia cases in a search for variants associated with treatment resistance or notably strong family history failed to identify any exonic variants (28). Gulisner et al. conducted exome sequencing in family constellations selected to maximize the chances of observing de novo mutations; no genes were identified, although there was a slight excess of de novo mutations predicted to damage proteins (61).

The task has proved more challenging than some investigators believed it would be a few years ago (62). A hypothetical model of the etiology of schizophrenia is that each case has a deterministic (possibly de novo) exon mutation. These mutations are very likely unique to individuals, although such mutations might show some bias for a selected but large set of genes. This model has been formally rejected for autism (63) and is rather inconsistent with



the accumulated data for schizophrenia. However, searches for this class of variation should be part of a balanced approach to understand the genetic basis of schizophrenia, as any such variant is likely amenable to molecular methods.

**GWASs.** The identification of candidate loci for complex diseases and traits has been accelerated by GWASs (15). As with other complex disorders (16, 64), common variation seems to be at the heart of the genetic risk of schizophrenia, and at least some of these associations replicate in samples from people of East Asian and European descent (30, 65). Large collaborations like the PGC have dramatically increased sample sizes and provided statistical power to identify relatively subtle effects of loci that meet an appropriately rigorous significance level ( $P < 5 \times 10^{-8}$ ). Indeed, there is a high-confidence exclusion zone (e.g., risk allele prevalence  $>0.1$  and genotypic relative risk  $>1.16$ ) in which no loci have been identified despite statistical power approaching 100% (Figure 1A, iv).

While understanding the determinants of schizophrenia may seem daunting, the emergence of themes among these regions is encouraging. For example, a recent GWAS (66) has identified 22 regions with genome-wide significance (Figure 1A, v), 13 novel regions and many that replicated previous findings (major histocompatibility complex [*MHC*], WW domain binding protein 1-like [*C10orf26*, also known as *WBP1L*], *DPYD-MIR137*, serologically defined colon cancer antigen 8 [*SDCCAG8*], *MMP16*, calcium channel, voltage-dependent, L-type,  $\alpha$ 1C subunit [*CACNA1C*], and a large region containing multiple genes and members of the inter- $\alpha$ -trypsin inhibitor heavy chain gene family [*ITIH3-ITIH4* region]) (18, 19, 24, 26, 67–69).

Several themes have emerged from the replicated GWAS findings, which provide a framework for future work. Calcium signaling has emerged as a potentially important theme in the etiology of schizophrenia. Calcium signaling has been previously implicated in bipolar disorder, autism, and schizophrenia (18, 19, 24, 70). A recent GWAS replicated the association of *CACNA1C* ( $\text{Ca}_v1.2$ ,  $P = 5.2 \times 10^{-12}$  at the intronic SNP rs1006737) with schizophrenia, and the  $\beta_2$  subunit ( $\text{Ca}_v \beta_2$ , encoded by *CACNB2*) also reached genome-wide significance ( $P = 1.3 \times 10^{-10}$  at the intronic SNP rs17691888) (20, 66). The voltage-gated L-type calcium channel is formed from the multimerization of the pore-forming  $\alpha_{1c}$  subunit (encoded by *CACNA1C*), which directly interacts with the intracellular  $\beta_2$  subunit (encoded by *CACNB2*), and a third extracellular membrane anchored  $\alpha_2\delta$  subunit (71, 72). Calcium channels have been extensively studied in neuroscience and are critically important for learning, memory, and synaptic plasticity (73–75). Several Mendelian disorders result from deleterious mutations in calcium channel subunits. Mutations in *CACNA1C* and *CACNB2* underlie Brugada syndrome types 3 and 4 (76). *CACNA1C* mutations cause Timothy syndrome, a multiorgan disorder, including cognitive impairment and autism spectrum disorder (70). Disruption of calcium channels can result in widespread effects, due to their known engagement in large protein networks at the synapse, as well as in multiple calcium-dependent signaling cascades.

The microRNA 137 (encoded by *MIR137*) has also emerged as a potentially important risk factor for schizophrenia, given its strong GWAS association with schizophrenia ( $P = 1.7 \times 10^{-12}$ ) (66). Given the known ability of microRNAs to regulate degradation or translational inhibition of large numbers of genes, it is notable that multiple proven and predicted miR-137 targets are also significantly associated with schizophrenia, including *CACNA1C*, transcription factor 4 (*TCF4*), CUB and Sushi multiple domains 1 (*CSMD1*), and

*C10orf26* (18, 77). miR-137 has been implicated in neurodevelopment, adult neural stem cell proliferation and differentiation, and dendritic arborization (78–80). These findings support future research ventures investigating the role of signaling pathways containing miR-137 targets in the pathogenesis of schizophrenia.

The current results strongly indicate that schizophrenia is highly polygenic, with disease burden being distributed across numerous loci (67). In the largest schizophrenia GWAS yet reported (21,246 schizophrenia cases and 38,072 controls), 22 loci reached genome-wide significance (66). Yet larger studies are in progress – the PGC has reported a preliminary GWAS mega-analysis of 25,000 schizophrenia cases and 28,000 controls and increased the number of genome-wide significance associations to 62 (81). The PGC is now preparing a report based on 36,000 schizophrenia cases and will increase the number of cases with GWAS data to 60,000. Bayesian power calculations based on empirical effect sizes project the identification of over 500 genome-wide significant and independent loci (66). Therefore, we expect considerable progress in this area in the next 1–2 years.

### The genetic architecture of schizophrenia

The nature of the genetic architecture of schizophrenia – the number of loci and the defining characteristics of each locus – has been debated for decades. We now have empirical data that directly addresses the underlying nature of schizophrenia. The polygenicity of schizophrenia is incontrovertible. Based on available data, the genetic architecture of schizophrenia is diverse and includes loci across the allelic spectrum (Figure 1): many common variants of subtle effect, rare but highly penetrant CNVs, and possibly exome variants.

Understanding the polygenicity of schizophrenia is a major task in the years to come. One parsimonious hypothesis is that one or more biological pathway(s) unifies many of the empirical findings for schizophrenia. However, the mechanisms by which these common variants increase risk for schizophrenia are still unknown. The biological roles of these variants and how they interact with other genes and the environment are not now understood.

The loci identified to date are probably a fraction of the variants that exist. Multiple studies have shown that cases have a greater burden of schizophrenia risk alleles compared with controls ( $P < 10^{-25}$ ) (30). We recently estimated that large numbers of independent and mostly common SNPs (95% credible intervals, 6,300–10,200 SNPs) underlie risk for schizophrenia (66). This estimate is supported by a recent study that estimated the number of SNPs with an effect on schizophrenia and bipolar disorder to be over 12,000 (82). Each SNP confers a very small increase in risk, but collectively they account for around 50% of the total variance in liability to schizophrenia (66). If the heritability of schizophrenia is around 65% (6, 8), this suggests that common genetic variation accounts for the lion's share of the heritability of schizophrenia.

### Sources of controversy

Genetic approaches to schizophrenia have been applied for over 40 years. Even casual readers in this area may be aware that dissecting the genetics of schizophrenia has been challenging. There have been many claims of identification of causal genetic risk factors for schizophrenia, and yet few claims prior to 2008 have stood the test of time and replication (83, 84). Such claims have occasionally





engendered considerable media attention. As one example, evidence from large and carefully conducted studies do not support *DISC1* as a risk factor for schizophrenia (27). A prominent exception that has shown robust and replicable associations with schizophrenia is the 22q11.2 del CNV present in approximately 0.3% to 2% of schizophrenia cases (34, 85).

We believe these difficulties and the attendant, unwelcome controversies have arisen for two main reasons. First, as discussed above, the genetic variants that increase risk for schizophrenia differ from what had often been assumed of a genetic architecture, with a prominent role for numerous loci of subtle effect. Despite significant efforts, there are no compelling examples of deterministic genetic variants acting in a Mendelian fashion as yet. From a statistical perspective, this genetic architecture implies that very large sample sizes are required (i.e., tens of thousands of cases) for any type of association study as well as for genome-wide linkage approaches (86, 87).

Thus, with the immense benefits of hindsight, the poor past replicability of genetic associations for schizophrenia can be at least partially understood on statistical grounds. If sample sizes are orders of magnitude too small, true associations will almost always be missed due to low power. Similarly, claims of association have an overwhelming probability of arising by chance and thus can be expected not to replicate. Since 2008, with the advent of far larger sample sizes, multiple genomic findings have replicated relatively well across samples.

A second source of controversy has arisen more recently. Multiple authors have argued that elucidation of genetic architectures for complex biomedical diseases (including schizophrenia) that are characterized by large numbers of common variants of subtle effects is effectively unhelpful (88, 89). The argument rests on two main points. The first point is the “missing heritability” objection that the identified variants explain only a small fraction of the variance in liability to a disorder. The counterargument is that if the genetic architecture has thousands of variants (as appears to be the case for many complex diseases) (15, 16, 64), models containing a small fraction of the thousands of truly associated variants could only explain small amounts of variation. Indeed, if modeled more inclusively, common variation can explain substantial fractions of the variance in liability, so that, effectively, variation is “hidden” by inadequately powered studies rather than “missing” (15, 64).

The second point is that elucidation of complex genetic architectures is unhelpful for attaining the goals of personalized (“precision”) medicine. The crux of this objection is the intention of conducting genomic searches: to generate rational biological starting points for idiopathic psychiatric disorders or to improve disease prediction and tailor treatments? The answer here depends on the researcher. Personalized medicine in regard to schizophrenia will be a difficult goal, given its genetic architecture. We note that this was predictable: the risk of schizophrenia to the co-twin of a monozygotic twin with schizophrenia is only around 50% (7), and this single observation strongly limits the potential role of genetic variation for personalized medicine. However, for many in the field, the primary goal of carrying out genetic studies has been biology. Each genetic finding is a potential etiological clue. Many of these findings will fall into a discrete number of biological, developmental, or functional pathways whose elucidation and characterization could dramatically advance knowledge of the pathophysiology of schizophrenia. As early examples of this, tran-

scriptional modules with altered gene expression in postmortem brain samples of individuals with schizophrenia (90) and autism (91) were enriched for smaller *P* values in GWAS.

### Clinical perspectives

The major implication of the schizophrenia findings to date is that the number of common variants potentially involved in increased risk for schizophrenia is in the thousands. While in silico approaches can yield initial hypotheses about these variants, bench research will be necessary for an understanding of the biology of the identified loci. Furthermore, the numerous relevant loci will need to be dissected, not with standard methods and individual efforts, but through the targeting of networks, like processes involving miR-137 and the calcium channel signaling pathway.

However, the immediate clinical implications are few. While currently available calcium channel antagonists have not demonstrated efficacy in the treatment of schizophrenia, this does not discount *CACNA1C* as a target for future research (92). Finally, one must consider that, as many approved antipsychotics increase the cardiac QT interval, genetic variation in calcium channel subunits could aid in the identification of patients at a higher risk of sudden cardiac death (93, 94).

Clinical assessment of several rare CNVs of strong effect could now be warranted. The identification schizophrenia cases with one of these variants (approximately 0.5%–2% of all cases) could potentially be relevant for reproductive decisions of patients upon genetic counseling, the etiology of psychiatric disorders in other family members, and evaluation of comorbid general medical diseases. For example, many of these CNVs are associated with epilepsy, and their presence should prompt particularly careful consideration of the cryptic presence of a seizure disorder. Although these CNVs should be uncommon in any clinical sample, the yield is probably higher than that shown by brain magnetic resonance imaging in first-episode psychosis that is commonly performed in many centers (95, 96).

### Emerging research directions

The new technologies, tools, and results from large samples have revitalized research into the fundamental basis of schizophrenia. As noted above, studies conducting more complete evaluation of the role of exonic variation should be published in 2014. Moreover, identifying parsimonious biological hypotheses — perhaps in the form of pathways whose dysfunction typifies schizophrenia — that might unify the polygenic findings for schizophrenia will likely become a major research focus, as any such pathways could provide considerable etiological insight and perhaps suggest new avenues for treatment interventions. We would like to highlight some of the avenues of research that might prove to be particularly informative in the near future.

First, we can now use genomic results in a research context to attempt to disentangle the notable but poorly understood clinical heterogeneity of schizophrenia. For example, it is now straightforward to assess individual “burden,” the number of common risk alleles, CNVs, and exonic deleterious variation. How do these measures of genetic liability to schizophrenia relate to symptom patterns, probability of treatment response, and clinical course?

Second, as noted above, schizophrenia results from both genetic and environmental sources of causation. We can measure environmental and genetic risk factors in populations. How



do specific environmental and genetic variables act to predispose or protect against schizophrenia? Are the effects additive or are there gene-environment interactions?

Third, we can now assess epigenetic variation (97) with considerable resolution. However, these studies remain expensive and have several notable experimental difficulties. These studies represent a “four-dimensional” problem in that they require sampling of the correct tissue at the appropriate point in time. Obtaining high-quality postmortem brain tissue is also nontrivial. Perhaps the most critical issue is delineating cause from consequence. Which epigenetic changes reflect the basic disease process and which result from a worse lifestyle, antipsychotic treatment, and/or drugs of abuse?

### Conclusions

In the last five years, the psychiatric genetics community has achieved remarkable progress in elucidating the genetic basis of schizophrenia. A convergence of factors facilitated these advances, including large-scale genome projects, technological innovations, and the accrual of large sample sets. We now have genomic data that directly address the underlying nature

of schizophrenia: the genetic architecture of schizophrenia is diverse and includes many common variants of subtle effect, some rare but highly penetrant CNVs, and possibly exome variants. This renewed understanding of the genetic architecture of schizophrenia has reinvigorated the psychiatric genetics community and promises to provide further insight into schizophrenia. Widespread collaboration will be necessary to assess the biological relevance of these genomic findings in order to facilitate maximal progress.

### Acknowledgments

We thank our colleagues worldwide (particularly in the Psychiatric Genomics Consortium), the tens of thousands of people who participated in the primary studies, and Thomas Lehner of the NIMH for his support. This work was supported by NIH grants U01 MH094421 and P50 HG006582.

Address correspondence to: Patrick F. Sullivan, Department of Genetics, CB#7264, 5097 Genomic Medicine, University of North Carolina, Chapel Hill, North Carolina 27599-7264, USA. Phone: 919.966.3358; Fax: 919.966.3630; E-mail: pfsullivan@med.unc.edu.

1. American Psychiatric Association. *Diagnostic Statistical Manual of Mental Disorders*. 4th ed. Washington, DC, USA: American Psychiatric Association Press; 1994.
2. World Health Organization. *The Global Burden of Disease: 2004 Update*. Geneva, Switzerland: WHO Press; 2008.
3. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. *Br J Psychiatry*. 1983; 142:465–470.
4. Regier DA, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the ECA study. *JAMA*. 1990;264(19):2511–2518.
5. Harris EC, Barraclough BB. Excess mortality of mental disorder. *Br J Psychiatry*. 1998;173:11–53.
6. Lichtenstein P, et al. Common genetic influences for schizophrenia and bipolar disorder: a population-based study of 2 million nuclear families. *Lancet*. 2009;373(9659):234–239.
7. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch Gen Psychiatry*. 2003;60(12):1187–1192.
8. Wray NR, Gottesman II. Using summary data from the danish national registers to estimate heritabilities for schizophrenia, bipolar disorder, and major depressive disorder. *Front Genet*. 2012;3:118.
9. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. *Eur Arch Psychiatry Clin Neurosci*. 2000;250(6):274–285.
10. Børglum AD, et al. Genome-wide study of association and interaction with maternal cytomegalovirus infection suggests new schizophrenia loci [published online ahead of print January 29, 2013]. *Mol Psychiatry*. doi:10.1038/mp.2013.2.
11. International HapMap Consortium. The International HapMap Project. *Nature*. 2003; 426(6968):789–796.
12. Durbin RM, et al. A map of human genome variation from population-scale sequencing. *Nature*. 2010;467(7319):1061–1073.
13. Lander ES, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001;409(6822):860–921.
14. Dunham I, et al. An integrated encyclopedia of DNA elements in the human genome. *Nature*. 2012; 489(7414):57–74.
15. Visscher PM, Brown MA, McCarthy MI, Yang J. Five years of GWAS discovery. *Am J Hum Genet*. 2012; 90(1):7–24.
16. Lander ES. Initial impact of the sequencing of the human genome. *Nature*. 2011;470(7333):187–197.
17. Psychiatric GWAS Consortium Steering Committee. A framework for interpreting genome-wide association studies of psychiatric disorders. *Mol Psychiatry*. 2009;14(1):10–17.
18. Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium. Genome-wide association study identifies five new schizophrenia loci. *Nat Genet*. 2011;43(10):969–976.
19. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat Genet*. 2011; 43(10):977–983.
20. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet*. 2013;381(9875):1371–1379.
21. Purcell SM, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748–752.
22. Walsh T, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. *Science*. 2008;320(5875):539–543.
23. Talkowski ME, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell*. 2012; 149(3):525–537.
24. Ferreira M, et al. Collaborative genome-wide association analysis of 10,596 individuals supports a role for Ankyrin-G (ANK3) the alpha-1C subunit of the L-type voltage-gated calcium channel (CACNA1C) in bipolar disorder. *Nat Genet*. 2008;40(9):1056–1058.
25. Williams HJ, et al. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. *Mol Psychiatry*. 2011;16(4):429–441.
26. Hamsheer ML, et al. Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCAG8, and extensive replication of associations reported by the Schizophrenia PGC. *Mol Psychiatry*. 2013;18(6):708–712.
27. Sullivan PF. Questions about DISC1 as a genetic risk factor for schizophrenia. *Mol Psychiatry*. 2013;18(10):1050–1052.
28. Need AC, et al. Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia. *Am J Hum Genet*. 2012;91(2):303–312.
29. Malhotra D, Sebat J. CNVs: harbingers of a rare variant revolution in psychiatric genetics. *Cell*. 2012;148(6):1223–1241.
30. Sullivan PF, Daly MJ, O'Donovan M. Genetic architectures of psychiatric disorders: the emerging picture and its implications. *Nat Rev Genet*. 2012;13(8):537–551.
31. Girirajan S, et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. *Nat Genet*. 2010;42(3):203–209.
32. Malhotra D, et al. High Frequencies of de novo CNVs in bipolar disorder and schizophrenia. *Neuron*. 2011;72(6):951–963.
33. Sebat J, et al. Strong association of de novo copy number mutations with autism. *Science*. 2007;316(5823):445–449.
34. Levinson DF, et al. Copy number variants in schizophrenia: Confirmation of five previous findings and new evidence for 3q29 microdeletions VIPR2 duplications. *Am J Psychiatry*. 2011;168(3):302–316.
35. Rujescu D, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. *Hum Mol Genet*. 2009;18(5):988–996.
36. Vacic V, et al. Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. *Nature*. 2011;471(7339):499–503.
37. Kirov G, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol Psychiatry*. 2012;17(2):142–153.
38. Rare chromosomal deletions and duplications increase risk of schizophrenia. *Nature*. 2008; 455(7210):237–241.
39. Stefansson H, et al. Large recurrent microdeletions associated with schizophrenia. *Nature*. 2008; 455(7210):232–236.
40. Mefford HC, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. *N Engl J Med*. 2008;359(16):1685–1699.
41. Brunetti-Pierri N, et al. Recurrent reciprocal 1q21.1 deletions/duplications associated with microcephaly or macrocephaly developmental behavioral abnormalities. *Nat Genet*. 2008;40(12):1466–1471.
42. Itsara A, et al. Population analysis of large copy number variants and hotspots of human genetic disease. *Am J Hum Genet*. 2009;84(2):148–161.
43. Luo R, et al. Genome-wide transcriptome profiling reveals the functional impact of rare de novo and recurrent CNVs in autism spectrum disorders. *Am J Hum Genet*. 2012;91(1):38–55.
44. Sanders SJ, et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with



- autism. *Neuron*. 2011;70(5):863–885.
45. Kirov G, et al. Support for the involvement of large copy number variants in the pathogenesis of schizophrenia. *Hum Mol Genet*. 2009;18(8):1497–1503.
46. Helbig I, et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. *Nat Genet*. 2009;41(2):160–162.
47. Mefford HC, et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. *PLoS Genet*. 2010;6(5):e1000962.
48. Williams NM, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. *Lancet*. 2010;376(9750):1401–1408.
49. McCarthy SE, et al. Microduplications of 16p11.2 are associated with schizophrenia. *Nat Genet*. 2009;41(11):1223–1227.
50. Weiss LA, et al. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med*. 2008;358(7):667–675.
51. Marshall CR, et al. Structural variation of chromosomes in autism spectrum disorder. *Am J Hum Genet*. 2008;82(2):477–488.
52. Kumar RA, et al. Recurrent 16p11.2 microdeletions in autism. *Hum Mol Genet*. 2008;17(4):628–638.
53. Shinawi M, et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, abnormal head size. *J Med Genet*. 2010;47(5):332–341.
54. Moreno-De-Luca D, et al. Deletion 17q12 is a recurrent copy number variant that confers high risk of autism schizophrenia. *Am J Hum Genet*. 2010;87(5):618–630.
55. Debbane M, Glaser B, David MK, Feinstein C, Eliez S. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological behavioral implications. *Schizophr Res*. 2006;84(2–3):187–193.
56. Raychaudhuri S, et al. Accurately assessing the risk of schizophrenia conferred by rare copy-number variation affecting genes with brain function. *PLoS Genet*. 2010;6(9):e1001097.
57. Golzio C, et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. *Nature*. 2012;485(7398):363–367.
58. Xu B, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. *Nat Genet*. 2012;44(12):1365–1369.
59. Xu B, et al. Exome sequencing supports a de novo mutational paradigm for schizophrenia. *Nat Genet*. 2011;43(9):864–868.
60. Girard SL, et al. Increased exonic de novo mutation rate in individuals with schizophrenia. *Nat Genet*. 2011;43(9):860–863.
61. Gulsuner S, et al. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. *Cell*. 2013;154(3):518–529.
62. Gratten J, Visscher PM, Mowry BJ, Wray NR. Interpreting the role of de novo protein-coding mutations in neuropsychiatric disease. *Nat Genet*. 2013;45(3):234–238.
63. Neale BM, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature*. 2012;485(7397):242–245.
64. Stahl EA, et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. *Nat Genet*. 2012;44(5):483–489.
65. Shi Y, et al. Common variants on 8p12 and 1q24.2 confer risk of schizophrenia. *Nat Genet*. 2011;43(12):1224–1227.
66. Ripke S, et al. Genome-wide association analysis identifies 13 new risk loci for schizophrenia [published online ahead of print August 25, 2013]. *Nat Genet*. doi:10.1038/ng.2742.
67. International Schizophrenia Consortium, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460(7256):748–752.
68. Stefansson H, et al. Common variants conferring risk of schizophrenia. *Nature*. 2009;460(7256):744–747.
69. Shi J, et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. *Nature*. 2009;460(7256):753–757.
70. Splawski I, et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell*. 2004;119(1):19–31.
71. Bidaud I, Mezghrani A, Swayne LA, Monteil A, Lory P. Voltage-gated calcium channels in genetic diseases. *Biochim Biophys Acta*. 2006;1763(11):1169–1174.
72. Turner RW, Anderson D, Zamponi GW. Signaling complexes of voltage-gated calcium channels. *Channels (Austin)*. 2011;5(5):440–448.
73. Moosmang S, et al. Role of hippocampal Cav1.2 Ca<sup>2+</sup> channels in NMDA receptor-independent synaptic plasticity spatial memory. *J Neurosci*. 2005;25(43):9883–9892.
74. White JA, McKinney BC, John MC, Powers PA, Kamp TJ, Murphy GG. Conditional forebrain deletion of the L-type calcium channel CaV1.2 disrupts remote spatial memories in mice. *Learn Mem*. 2008;15(1):1–5.
75. Mangoni ME, Couette B, Marger L, Bourinier E, Striessnig J, Nargeot J. Voltage-dependent calcium channels and cardiac pacemaker activity: from ionic currents to genes. *Prog Biophys Mol Biol*. 2006;90(1–3):38–63.
76. Perrin MJ, Gollob MH. Genetics of cardiac electrical disease. *Can J Cardiol*. 2013;29(1):89–99.
77. Kwon E, Wang W, Tsai LH. Validation of schizophrenia-associated genes CSMD1, C10orf26, CACNA1C, and TCF4 as miR-137 targets. *Mol Psychiatry*. 2013;18(1):11–12.
78. Willemsen MH, et al. Chromosome 1p21.3 microdeletions comprising DPYD MIR137 are associated with intellectual disability. *J Med Genet*. 2011;48(12):810–818.
79. Silber J, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. *BMC Med*. 2008;6:14.
80. Szulwach KE, et al. Cross talk between microRNA and epigenetic regulation in adult neurogenesis. *J Cell Biol*. 2010;189(1):127–141.
81. Ripke S, Ruderfer D. Dissection of Genetic Architecture of Bipolar Disorder and Schizophrenia. In: *World Congress of Psychiatric Genetics*. Hamburg, Germany; 2012.
82. Andreassen OA, et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. *PLoS Genet*. 2013;9(4):e1003455.
83. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. *Nat Genet*. 2001;29(3):306–309.
84. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. *Mol Psychiatry*. 2004;9(1):14–27.
85. Karayiorgou M, Simon TJ, Gogos JA. 22q11.2 microdeletions: linking DNA structural variation to brain dysfunction schizophrenia. *Nat Rev Neurosci*. 2010;11(6):402–416.
86. Risch N, Merikangas KR. The future of genetic studies of complex human diseases. *Science*. 1996;273(5281):1516–1517.
87. Wray NR, Visscher PM. Narrowing the boundaries of the genetic architecture of schizophrenia. *Schizophr Bull*. 2010;36(1):14–23.
88. Goldstein DB. Common genetic variation and human traits. *N Engl J Med*. 2009;360(17):1696–1698.
89. McClellan J, King MC. Genomic analysis of mental illness: a changing landscape. *JAMA*. 2010;303(24):2523–2524.
90. Roussos P, Katsel P, Davis KL, Siever LJ, Haroutunian V. A system-level transcriptomic analysis of schizophrenia using postmortem brain tissue samples. *Arch Gen Psychiatry*. 2012;69(12):1205–1213.
91. Voineagu I, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. *Nature*. 2011;474(7351):380–384.
92. Imbrici P, Camerino DC, Tricarico D. Major channels involved in neuropsychiatric disorders and therapeutic perspectives. *Front Genet*. 2013;4:76.
93. Koponen H, et al. Schizophrenia and sudden cardiac death: a review. *Nord J Psychiatry*. 2008;62(5):342–345.
94. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. *Int Clin Psychopharmacol*. 2005;20(5):243–251.
95. Woolley J, McGuire P. Neuroimaging in schizophrenia: what does it tell the clinician? *Adv Psychiatr Treat*. 2005;11:195–202.
96. Albon E, et al. Structural neuroimaging in psychosis: a systematic review and economic evaluation. *Health Technol Assess*. 2008;12(18):iii–iv, ix–163.
97. Petronis A. Epigenetics as a unifying principle in the aetiology of complex traits and diseases. *Nature*. 2010;465(7299):721–727.
98. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. *PLoS Med*. 2005;2(5):e141.
99. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. *Am Heart J*. 2005;150(6):1115–1121.
100. Jeste DV, Gladsjo JA, Lindamer LA, Lacro JP. Medical comorbidity in schizophrenia. *Schizophr Bull*. 1996;22(3):413–430.
101. van Os J, Kapur S. Schizophrenia. *Lancet*. 2009;374(9690):635–645.
102. Wu EQ, et al. The economic burden of schizophrenia in the United States in 2002. *J Clin Psychiatry*. 2005;66(9):1122–1129.